Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Akero Therapeutics Inc (AKRO)
Akero Therapeutics Inc (AKRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,520,610
  • Shares Outstanding, K 55,700
  • Annual Sales, $ 0 K
  • Annual Income, $ -112,030 K
  • 60-Month Beta -0.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.42
Trade AKRO with:

Options Overview Details

View History
  • Implied Volatility 126.72% ( +2.80%)
  • Historical Volatility 84.81%
  • IV Percentile 89%
  • IV Rank 43.40%
  • IV High 243.46% on 10/06/23
  • IV Low 37.22% on 06/23/23
  • Put/Call Vol Ratio 0.57
  • Today's Volume 252
  • Volume Avg (30-Day) 678
  • Put/Call OI Ratio 1.06
  • Today's Open Interest 15,189
  • Open Int (30-Day) 14,984

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.82
  • Number of Estimates 5
  • High Estimate -0.67
  • Low Estimate -1.01
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -67.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.32 +77.74%
on 02/06/24
27.98 -2.68%
on 02/28/24
+5.11 (+23.10%)
since 01/26/24
3-Month
15.32 +77.74%
on 02/06/24
27.98 -2.68%
on 02/28/24
+10.71 (+64.83%)
since 11/28/23
52-Week
11.25 +142.04%
on 10/27/23
58.38 -53.36%
on 06/13/23
-18.28 (-40.17%)
since 02/28/23

Most Recent Stories

More News
Why Akero Therapeutics Shares Are Slumping This Week

Akero's lead therapy fell short of its goals in a phase 2b trial to treat NASH.

AKRO : 27.23 (-0.26%)
Stocks End Higher on an Improved Outlook for a Fed Pause

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.52%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

$SPX : 5,069.76 (-0.17%)
SPY : 506.26 (-0.13%)
$DOWI : 38,949.02 (-0.06%)
DIA : 389.60 (-0.02%)
$IUXX : 17,874.50 (-0.54%)
QQQ : 435.27 (-0.53%)
TFC : 34.81 (-0.20%)
COHR : 57.97 (-0.09%)
H : 152.24 (+0.51%)
RIVN : 11.30 (+1.44%)
BA : 207.00 (+2.78%)
CCL : 15.47 (-2.77%)
PepsiCo, Palantir rise; Neogen, Akero Therapeutics fall, Tuesday, 10/10/2023

Stocks that traded heavily or had substantial price changes on Tuesday: PepsiCo, Palantir rise; Neogen, Akero Therapeutics fall

PGTI : 41.78 (+0.05%)
AKRO : 27.23 (-0.26%)
NEOG : 17.12 (-0.87%)
PEP : 167.03 (-0.67%)
Why Shares of 89bio Plummeted on Tuesday

So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.

AKRO : 27.23 (-0.26%)
ETNB : 11.76 (+0.17%)
Why Akero Therapeutics Stock Is Crashing Today

Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).

ETNB : 11.76 (+0.17%)
AKRO : 27.23 (-0.26%)
Stocks Gain on the Outlook for Pause in Fed Rate Hikes

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.71%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.83%. Stocks...

$SPX : 5,069.76 (-0.17%)
SPY : 506.26 (-0.13%)
$DOWI : 38,949.02 (-0.06%)
DIA : 389.60 (-0.02%)
$IUXX : 17,874.50 (-0.54%)
QQQ : 435.27 (-0.53%)
TFC : 34.81 (-0.20%)
COHR : 57.97 (-0.09%)
H : 152.24 (+0.51%)
RIVN : 11.30 (+1.44%)
CCL : 15.47 (-2.77%)
EA : 140.08 (+0.42%)
Markets Today: Stocks Slightly Higher on Prospects of Additional China Stimulus

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are up +0.05%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are up +0.04%. Stock index futures this morning are slightly higher on the prospects...

ESH24 : 5,067.75 (-0.26%)
NQH24 : 17,871.50 (-0.24%)
PEP : 167.03 (-0.67%)
BABA : 74.59 (-3.98%)
JD : 22.81 (-5.27%)
NTES : 112.28 (-0.76%)
BIDU : 103.31 (-8.05%)
TCOM : 44.46 (+0.32%)
PDD : 125.01 (-2.59%)
COHR : 57.97 (-0.09%)
EXAS : 56.31 (-1.04%)
EA : 140.08 (+0.42%)
Stock Index Futures Climb on Dovish Fed Comments, PepsiCo Earnings on Tap

December S&P 500 futures (ESZ23) are up +0.20%, and December Nasdaq 100 E-Mini futures (NQZ23) are up +0.26% this morning as comments from Fed officials bolstered bets that the U.S. central bank may stand...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
ZS : 237.29 (-2.14%)
NOC : 458.95 (+0.13%)
LMT : 432.48 (+0.48%)
DAL : 42.01 (+0.07%)
AAL : 15.46 (-0.51%)
DDOG : 130.47 (-0.37%)
PEP : 167.03 (-0.67%)
ELIS.FP : 20.980 (+0.10%)
IMUX : 1.4000 (+0.72%)
AKRO : 27.23 (-0.26%)
3 Mid Caps You Haven't Heard Of But Need To Know About

Here are three mid-cap stocks that will not have been on the radar for most readers but whose recent performance warrants closer inspection and consideration.

AAPL : 181.42 (-0.66%)
AKRO : 27.23 (-0.26%)
META : 484.02 (-0.62%)
AI : 29.69 (-1.36%)
TSLA : 202.04 (+1.16%)
JOBY : 5.51 (-3.16%)
Here's Why Momentum in Akero Therapeutics, Inc. (AKRO) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, Akero Therapeutics, Inc. (AKRO) could be a great choice. It is one of the several stocks that passed through our...

AKRO : 27.23 (-0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which...

See More

Key Turning Points

3rd Resistance Point 28.92
2nd Resistance Point 28.45
1st Resistance Point 27.84
Last Price 27.23
1st Support Level 26.76
2nd Support Level 26.29
3rd Support Level 25.68

See More

52-Week High 58.38
Fibonacci 61.8% 40.38
Fibonacci 50% 34.82
Fibonacci 38.2% 29.25
Last Price 27.23
52-Week Low 11.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar